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SUMMARY 
In this dissertation, the discriminant values of four methods of CKMB measurement and 
quaUtative Troponin-T for the early diagnosis of acute myocardial infarction (AMI) were 
compared. In the case of CKMB measurement, CKMB mass concentration assay was 
performed using Abbott EMx，CKMB activity concentration assays were performed using 
Dupont aca ion-exchange chromatography (ffiC) plus immunoinhibition method, Hitachi 
911 reagent-start immunoinhibition method (with true serum blanking ) and Hitachi 911 
sample-start immunoinhibition method (without serum blanking). In the case of Troponin-
T measurement, a very recently available dry chemistry system for rapid qualitative 
measurement of cardiac troponin-T was performed in the CCU. The study subjects 
comprised 76 patients admitted to the cardiac care unit with suspected AMI. 54 of them 
were finaUy classified as AMI and the remaining 22 as non-AMI. Thus the prevalence of 
AMI in CCU was 71%. Comparison ofthe analytical performance of the CKMB methods 
showed that Hitachi 911 methods had the best precision, while the Abbott JMx method 
had the best result in the interference studies examining the effects of haemoglobin, 
bilirubin and Upaemia. In the clinical evaluation study, Troponin-T showed a striking 100% 
specificity comparable to ECG. But the general performance of CKMB methods in the 
clinical trial were better than qualitative Troponin in admission samples in term of 
i • 
diagnostic efficiency . ROC curves were generated for CKMB methods for the admission 
I and post 2-hour samples. Their performance in the admission samples relative to each 
8 
other did not show any statistically significant differences. Both Abbott m x and Dupont 
aca showed better discriminating power than the Hitachi 911 methods in the 2-hour 




1.1 Acute Myocardial Infarction 
Acute myocardial infarction (AMI) generally occurs with the sudden decrease in coronary blood flow that follows a thrombotic occlusion of a 
coronary artery previously narrowed by atherosclerosis. Progression of the atherosclerotic 
lesion to the point where thrombus formation occurs is a complex process related to 
{ vascular injury. This injury is produced or facilitated by factors such as cigarette smoking, 
hypertension, and lipid accumulation [1]. 
Li the majority of cases，infarction occurs when an atherosclerotic plaque fissures, 
ruptures, or ulcerates, and，with conditions favouring thrombogenesis ( factors which may 
be local or systemic), a mural thrombus forms leading to coronary artery occlusion. 
Despite progress in the reduction of coronary vascular disease，acute myocardial 
infarction (AMI) remains a major source of morbidity and mortality [2]. In Hong Kong, a 
recent morbidity survey in June 1995 showed that cardiovascular disease is one of the top 
three killers [3]. Li a westem country such as the U.S.A. approximately 4 miUion 
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Americans will be evaluated for chest pain each year, of whom 1.5 miUion wiU have AMJ^ 
and half a million wiU die [4]. Half of the deaths occur before the patients reach the 
hospital; and in the longer term, an additional 5 to 10 percents of survivors wiU die in the 
first year foUowing infarction. 
The goal of therapy is to restore coronary artery blood flow, limit the size of 
infarction, and salvage the myocardium. New therapeutic interventions, specificaUy 
thrombolytic agents such as streptokinase and tissue plasminogen activator can reduce the 
incidence of morbidity and death [5]. Low dose aspirin and beta blockers (if heart failure is 
absent) also reduce mortality [6]. Percutaneous transluminal coronary angioplasty (PTCA) 
can be used as an emergency intervention if coronary patency fails to be restored by 
pharmacological interventions. 
i Therapeutic goals are best achieved when intervention is early relative to onset of 
the acute clinical features. For a patient to derive maximum benefit from thrombolytic 
therapy, treatment within 4 to 6 hours after infarction is essential [7]. Moreover, 
thrombolytic and antiplatelet therapies and PTCA carry some risk, and optimal benefits are 
obtained ifthey are applied to appropriately selected patients early in the course of AMI. 
This potential for therapeutic intervention places further pressure on clinicians to 
mak« an increasingly rapid and accurate diagnosis of AMI on initial presentation. 
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1.2 Diagnosis ofAcute Myocardial Infarction (AMD 
Diagnosis of an AMI is usually based on World Health Organization (WHO) 
criteria. [8,9] Li summary, it is the presence of at least 2 of3 classic findings 
1. Clinical history ofischaemic chest discomfort of more than 30 minutes duration. 
2. Evolution oftypical, unequivocal electrocardiographic changes. 
3. Increase of serum enzymes indicative of myocardial muscle cell injury. 
1.2.1 Clinical signs 
Not aU cases of AMI present with the typical clinical features. The Framingham 
study [10] and the Multiple Risk Factor Trial (MRFIT) [11] have indicated that as many as 
1 in 3 AMIs are not cHnicaUy recognized by either patient or physician because the chest 
pain is atypical or absent. 
The incidence of silent myocardial infarction is higher in diabetic patients [12]. 
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The classical electrocardiographic(ECG) features (ST elevation plus development 
of new Q waves) have 100% specificity for the diagnosis of definite AMI. However, in 
patients with presumed AMI, ECG findings are often non-diagnostic. This is especiaUy 
true for non-Q wave AMI when classical ST elevation may be absent. For example, ST 
depression over several leads is a non-specific fmding that may represent only ischaemia; 
but it is also consistent with extensive subendocardial infarction which has a poor 
prognosis [13]. 
Diagnostic accuracies of ECG vary in different reports. When only the admission 
ECG is considered in patients with prolonged chest pain and no prior infarction, the 
overaU efficiency could be as high as 75% [14]. With retrospective assessment of serial 
ECGs, by which time it may be too late for therapeutic interventions, the efficiency is 
increased to 94% [15]. 
On the other hand，according to others the ECG is misleading on admission in at 
least 8% of all AMI patients and is indeterminate in an additional 12% of patients, 
primarily because of the presence of left bundle branch block or nonspecific ST-T wave 
^ abnormalities [15]. Almost 50% of patients with AMI will initially have nondiagnostic 
ECGs on emergency department presentation [16]. 
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1.2.3 Cardiac enzymes 
After acute myocardial infarction, concentrations of cardiac enzymes and non-
enzymatic proteins in serum reflect leakage of enzymes from damaged myocardial cells. 
Different enzymes and proteins reach peak levels in serum at different times after AMI. 
The routine enzyme measurements used for investigation of AMI are total LD, total CK 
and AST activities. 
Measurements of cardiac enzymes start from the report of Karmen et al in 1954 
[17]. Serum glutamate oxaloacetate transaminase (SGOT, now aspartate transaminase or 
AST ) activity was increased in the serum of patients with AMI, which stimulated an 
explosion in diagnostic testing. Because of greater specificity for heart, measurement of 
the isoenzymes of lactate dehydrogenase (now designated LD) has replaced AST for the 
appearance of confirmation of myocardial injury in many US centres [18]. However, the 
rapid appearance of CK in serum after AMI [19] and the improved specificity for 
myocardial injury provided by measurement of the MB isoenzyme [22] made CKMB a 
preferred marker . 
The search for new markers to detect AMI has been intensive over the past decade. 
A number of enzymes and proteins are being tested for vaHdity as good biochemical 
markers (Table 1) [21]. 
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Table 1. Examples of biochemical markers of AMI 
“ “ Myoglobin~"CKMB LD1 Troponin-T 
MolecularWeight 17800 86000~~~135000 18000~~ 
Increase, in hours 1-4 3-8 8-12 4_6 
Peak, in hours 6-7 10-24 72-144 10-24 
retum to normal, in day 1 3^4 8-14 10-15 
An ideal marker of choice should 
1. be found in high concentration in myocardium. 
2. not be found in other tissues，even in trace amounts or under pathological conditions. 
3. be released rapidly after myocardial injury. 
4. be released in direct proportion to the extent of myocardial injury. 
5. persist in plasma for several hours to provide a convenient diagnostic time window but 
not so long that recurrent injury would not be identified. 
1.3 CKMB, the marker of choice 
CKMB has been the accepted standard as the biochemical marker of AMI for more 
than 10 years ago, but its status as “ king of the markers" is now being challenged [22:. 
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The evolution of CKMB has been exciting, and its evaluation continues to be challenging. 
The recommended and most accepted protein marker for AMI in the world today is still 
CKMB [23]. 
Advances in technology and the development of monoclonal antibodies have been 
responsible for the shifts from qualitative assessment of CKMB, to quantitative 
0 
measurement of CKMB activity，and then to quantitative measurement of its mass 
concentration [24]. 
There are, in fact, numerous methods used to separate and mea3ure CKMB. 
Previously, manual methods such as electrophoresis and ion-exchange column 
chromatography were used. These are not suitable for the rapid testing needed for early 
diagnosis because they have poor analytical sensitivity, and are labour-intensive and time 
consuming. A variety of commercial immunochemical methods have gained, and some 
lost, acceptance in the cUnical laboratory because of the required criteria for testing of 
precision, analytical specificity, sensitivity, cardiac specificity, turnaround time and stabiHty 
of reagents. The availabiHty of monoclonal antibodies specific for CKMB has contributed 
to the development of assays capable of measuring activity and mass concentration of this 
isoenzyme. An important practical advantage of immunochemical assays is that they are 
adaptable to automated analyzers, and therefore have the potential of rapid turnaround 
time, analytical reproducibility, and ease of operation. 
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tamunochemical methods for CKMB can be classified according to various assay 
components including: (1) the types of antibody, that is, monoclonal or polyclonal, which 
determine the specificity of the assay; (2) the separation methods for removing free from 
bound reactants; (3) type of measurement, that is，direct or indirect and (4) labels such as 
enzymes, fluorescent molecules, and chemiluminescent compounds used for detection and 
quantification. 
Depending on the particular configuration of the above components, immunoassays 
available in the market today vary in analytical sensitivity (detection Hmit), and specificity 
(selectivity for antigen), reproducibiUty, time of analysis，ease of use, and most important 
of all, costing. Therefore, there is a necessity to directly compare some methods available 
，before the implementation of this new test for early diagnosis of AMI. 
1.4 Troponin-T, another candidate marker 
Cardiac Troponin-T (cTnT) is a 37-kDa polypeptide subunit of the myofibriUar 
regulatory troponin complex [25]. It is one of the three major types (Troponin-C, 
Troponin-I, Troponin-T) found in striated muscle. Since most of the Troponin complex is 
bound to contractile elements, a prolonged release of Troponin foUowing AMI is 
expected due to the destruction and clearance of structural elements from muscle ceUs. 
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However, a smaU amount of Troponin is present free in the cytoplasm, and this may be 
released within the first few hours after cell injury[26]. 
When compared with CKMB, the number of methods available for Troponin is 
very limited. Assays for measuring serum concentrations of cardiac Troponin-T [27] and 
cardiac Troponin-I (cTnT) [28] have been reported. Research assays for cTnT have led to 
the development of an automated 90-minute immunoassay [29] . Clinical trials conducted 
in Europe have reported the use ofcTnT for the detection of AMI [30]. 
A qualitative test for cTnT (TropT ® Rapid Assay) became available on the market 
in 1995 manufactured by Boerhinger Mannheim Diagnostics (BMD). 
1.5 Objectives 
• to compare the analytical performance of the various methods of CKMB measurement 
I in this experiment 
• to find out whether including serum blanking in 911 reagent-start method can greatly 
reduce the effect of interference by haemolysis. If so，then use of enzymatic method for 
CKMB measurement is preferred, because the price is comparatively lower than other 
methods 
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• to establish reference ranges for the four methods of CKMB measurement in Hong 
Kong 
• to evaluate the new qualitative Troponin-T for diagnosing AMI 
• to compare the clinical performance among various CKMB methods and between 
CKMB and Troponin-T 
1 19 
Chapter 2 • 
ANALYTICAL EVALUATION OF CKMB BY THE 
FOUR METHODS 
2.1 Analytical methods ： 
In this experiment, assay of total CK and the four methods of CKMB were 
performed by the author, while the assay for Troponin-T was performed by nurses in 
ccu. 
2.1.1 Assay for total creatine kinase 
Analyser used: Hitachi 911 
Reagent kit: CK NAC-activated Cat. No. 1273248 
Test principle: in the presence of CK at pH 6.7, the phosphate group from creatine 
phosphate is transferred to ADP[31]; the ATP produced in the reverse reaction is 
measured by coupHng the hexokinase (HK) and the GPD reactions to CK reaction. The 
hexokinase cataalyzes phosphorylation of glucose by ATP to form G-6-P and regenerates 
ADP for the CK reaction. The G-6-P is then oxidized with NADP+ to form 6-
phosphogluconic acid and NADPH. The rate ofNADPH formation is a measure ofthe CK 
20 
activity, provided that the concentrations of all other components in the three-enzyme 
system are present in suitable excess, so that the CK activity is the only limiting factor. The 
reaction equations are as follow. 
CK 
Creatine phosphate + ADP > creatine + ATP 
pH6.7 
HK 
ATP + glucose > glucose-6-phosphate + ADP 
GPD 
Glucose-6- phosphate + NADP+ > 6-phosphogluconate + NADPH + H^ 
2.1.2 Assay for CKMB 
There are four methods being employed in this experiment, as follow 
2.1.2.1 Method 1 : CKMB mass concentration assay 
Analyser used: Abbott IMx 
i Reagent: JMx STAT CK-MB Reagent Pack，No. 7A28-20 
Test principle: The Abbott JMx stat CKMB mass assay [32] is a two-step automated 
microparticle enzyme immunoassay for use with the Abbott JMx analyzer[33]. In the initial 
incubation, CKMB present in serum or plasma is captured using monoclonal anti-CKMB 
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coated latex particles (production and characterization of this antibody described in detail 
by Baidya et al.,[34] . The microparticle sample mixture is transferred to the glass fibre 
matrix of the JMx disposable cuvette and polyclonal anti-CKMM alkaline phosphatase 
conjugate is added. After additional incubation and washing the product of alkaHne 
phosphatase catalysis, 4-methylumbelliferone, is detected fluorometricaUy and quantitated 
with the JMx analyzer (microparticle enzyme immunoassay technology). 
2.1.2.2 Method 2 : CKMB EEC ( Ion Exchange Chromatography) & 
Immunoinhibition activity assay 
Analyser used : Dupont aca 
Reagent kit: CKMB reagent kit cat. no. 705718901 
Test principle: this CKMB method uses a combination of ion exchange chromatography 
and immunoinhibition to achieve a highly specific measurement of CKMB in serum[35]. 
The separation of CK isoenzymes from serum occurs in the head of the pack using a 
column containing a mixture of diethylaminoethyl (DEAE) and carboxylic acid resins. The 
pH, ionic strength and resin ratio of the column are balanced to reproducibly separate 
CKMB from CKMM and CKBB. The column also retains red ceU and muscle adenylate 




The specificity of the CKMB method is further enhanced by including in the 
pack reagents antibody to ' M " subunit of human CK isoenzymes to inhibit any residual 
CKMM that may not be retained by the column. 
Activity of the CK-B catalyzes the reversible transfer of phosphate from 
creatine phosphate to adenosine-diphosphate producing adenosine triphosphate(ATP). The 
ATP phosphorylates glucose to produce glucose-6-phosphate in a reaction catalyzed by 
hexokinase. The resulting glucose-6-phosphate reduces NAD (nicotinamide adenine 
dinucleotide) to NADH in a reaction catalyzed by glucose-6-phosphate dehydrogenase. 
The rate of change of absorbance at 340nm due to the formation of NADH is directly 
proportional to the CKMB activity. 
CKMB + Ab > CKMB:Ab (only M-subunit being inhibited) 
• 
CKMB:Ab 
Creatine phosphate + ADP > Creatine + ATP 
Mg2+，DTE 
HK 
ATP + Glucose > ADP + G-6-P 
Mg2+ 
G6PDH 
G-6-P + NAD+ > 6-phosphogluconate + NADH + fT 
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The reagent concentraions in the pack are non-rate-limiting and are 
optimized for measurement ofCKMB. Dithioerythritol (Cleland's reagent) is present as an 
activator and N-2-acetamido-2-aminoethanesulphonic acid as buffer. Adenosine 
monophophate and l,5-di(adenosine-5-pentaphosphate) are included to inhibit adenylate 
kinase (AK). 
2.1.2.3 Method 3 : CKMB activity concentration assay 1 
Analyser used : Hitachi 911 
Reagent kit: CKMB ^^AC-activated) immunoassay with sample-start(SS) method Cat. 
no.1442392 
Test principle: CKMB is composed of the two moieties CK-M and CK-B. A specific 
antibody inhibits the CK-M moiety without affecting the CK-B moiety. The CK-B fraction 
accounts for one haLf the activity of CKMB; it is determined then by the NAC-activated 
method [36], This is the same method employed for assaying total CK. For this 
immunoinhibition method to be valid one must assume the absence of interfering 
substances such as CK-BB，macro or mitochrodrial CKs and，most importantly，AK. 
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2.1.2.4 Method 4 : CKMB activity concentration assay 2 
Analyzer used: Hitachi 911 
Reagent kit: CKMB (NAC-activated) immunoassay with reagent-start(RS) method Cat. 
No. 1127608 
Test principle: CKMB consists of the subunits CK-M and CK-B. By means of a specific 
antibody the CK-M subunits are inhibited without the CK-B subunits being affected. The 
remaining CK-B activity, which corresponds to half of the CKMB activity，is determined 
using the CK NAC activated method [36]. This method is different with respect to method 
3 in that the this method uses “true” serum blanking, in the hope of reducing the AK effect 
due to haemolysis. Creatine phosphate, the substrate of the CK reaction, is added only 
after monitoring the initial rate of formation of NADH in the reaction mixture, the latter 






AEM : To verify the precision of the four methods employed in measuring CKMB，with 
.t 







. . 1 
. 1 
abiUty of a method to repeat a value for a sample regardless ofwhere that sample is placed 
within a run. Between-run precision evaluates the ability of a method to repeat 
measurements when aHquots are placed on different runs. 
2.2.1 Within-run precision 
METHODS : Low，medium and high levels of pooled patient serum were used separately 
in three individual runs. There were twenty repUcates in each run. Every samples was 
assayed for CKMB by the four methods. 
RESULTS : the within-run precision of the four methods of CKMB measurement can be 
found from table 2.2.1. For all methods involved, there was a common finding that the % 
CV was decreasing with increasing concentration of CKMB. The percent CV ranged from 
3.3 to 5.0 for the Abbott JMx method，1.6 to 7.9 for the Dupont aca method，1.0 to 2.5 
for the Hitachi 911 reagent-start method, 0.6 to 2.9 for the Hitachi 911 sample-start 
method. It seemed that the methods on the Hitachi 911 had the best performance in this 
26 
• 1 
regard. The performance of Dupont aca at low level of CKMB (near to the upper normal 
range) was inferior to the other methods. 
The manufacturer claim for Abbott EMx within-run precision at low， 
medium and high control were 5.1，3.7,and 3.3 respectively. No data were available for 
Dupont aca and Hitachi 911 methods for comparison. Also, the low level sera employed in 
this experiment had a level near to the upper reference range. Therefore，precision at this 
level was cHnicaUy important. 
Table 2.2.1 : within-run precision of the four methods of CKMB measurement 
Methods Level of sera Mean value 9 (units) SD CV (%) 
Abbott EVbc Low 5.8 ng/mL 0.29 5.0 
Medium 21.2ng/mL 0.78 3.7 
High 95 ng/mL 3 3.3 
Dupont aca Low 5.0U/L 0.39 7.9 
Medium l2.9JJfL 0.54 4.2 
High 75.7U/L 1.2 1.6 
Hitachi911-RS Low 27.5 U/L 0.69 2.5 
Medium 49.6 \JfL 1.05 2.1 
High 149U/L 1.50 1.0 
Hitachi911-SS Low 29.4 U/L 0.85 2.9 
Medium 55.9U/L 0.72 1.3 
High 181 U/L 1.07 0.6 
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2.2.2 Between-run precision 
METHODS : Control materials were used in this study. For Abbott JMx, tri-level Abbott 
control sera were employed. For Dupont aca，Biorad control (level 1 and level 2) were 
employed. Finally, for Hitachi 911 reagent-start method and sample-start method, low 
level pooled patient serum and BM Precinorm were used. 
RESULT : the between-run precision results ofthe four methods of CKMB measurement 
can be found in table 2.2.2 • There was a parallel finding with the within-run precision in aU 
methods: it was the decreasing percentage CV with increasing concentration of CKMB. 
The between-run precision ranged from 5.9 to 6.1 by the Abbott JMx method , 1. 3 to 4.6 
by the Dupont aca method，1.5 to 4.6 by the Hitachi 911 reagent-start method，1.2 to 4.4 
by the Hitachi 911 sample-start method. It appeared that the activity concentration 
methods, that is Dupont aca and Hitachi 911 methods, had better performance for 
between-run precision than the mass concentration method by JMx. 
The manufacturer claim for Abbott JMx between-run precision for low, 
medium and high control were 5.0, 7.5 and 8.0 respectively. No data were available for the 




Table 2.2.2 : between-run precision for the four methods of CKMB measurement 
Methods Sample type No. of sample Mean value SD CV (%) 
B ^ Abbott Low 53 5.1 0.3 6.1 
Abbott Medium 63 21.1 1.2 5.7 
Abbott High 56 131 7.7 5.9 
aca Biorad Level 1 20 21.5 0.99 4.6 
Biorad Level 2 20 57.8 0.75 1.3 
911-RS Low pooled 20 35.6 1.64 4.6 
BM Precinorm 39 210 3.2 1.5 
911-SS Low pooled 20 35.1 1.55 4.4 
BM Precinorm 32 206 2.5 1.2 




METHODS: The accuracy of various measurements were estimated by comparing the 
means and ranges of control results to the assigned values given by the manufacturer. 
29 
RESULTS: The performance of the CKMB measurements by the four methods are 
shown in Table 2.3.1. The mean measured CKMB levels were all within the assigned 
ranges and were actually very close to the mid-point of the assigned ranges given. The 
accuracy using the data from the respective manufacturer control results were satisfactory 
for all four methods of CKMB measurement. 
Table 2.3.1 : accuracy of the four methods of CKMB measurement 
“ CONTROL N ^ . O F ^ l S S s [ ™ ^ ? S — � i § i ^ E 5 ™ 
METHODS SAMPLE R ^ G E 
m x Low 53 5.1 4.4 - 5.6 3.5 - 6.5 ngy'mL 
Medium 63 21.1 19.2 - 24.6 15 -25 ng/mL 
High 56 131 121.4 - 145.5 90 - 150ng/mL 
aca Biorad 1 20 21.5 19.7 -23 19 -29U/L 
Biorad 2 20 57.8 56.7 - 59.2 44 - 66 UfL 
911-RS Precinorm 39 210 204 - 216 171 -257U/L 
911-SS Precinorm 32 206 200-211 171 -257U/L 
2.4 Linearity 
AEM: a linearity check is used to find the analytical range that is linear for routine 
measurements. 
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METHODS: Protocols from the National Committee on Clinical Laboratory Standards 
QS[CCLS) were used for checking linearity . A high CKMB patient sample or control 
material were used. Serial dilution by volume with a low CKMB patient sample was 
performed to obtain values down to levels approaching zero. Duplicate measurement of 
CKMB level was performed for each specimen prepared. 
RESULTS: the linearity ofeach methods can be.visualised from fig 2.4.1 to fig 2.4.4. For 
the Abbott M x method, the linearity was up to at least 300 ng/mL. For the Dupont aca， 
the linearity was up to at least 125 U/L. For the Hitachi 911 reagent-start method，the 
linearity was up to at least 839 U/L. For the Hitachi 911 sample-start method, the linearity 
was up to at least 600 U；^. 
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Fig 2.4.1: Linearity of CKMB mass concentration by Abbott JMx 
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Fig 2.4.2 : Linearity of CKMB activity concentration by Dupont aca 
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Fig 2.4.3 : Linearity of CKMB activity concentration by Hitachi 911 reagent-start 
method 
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Fig 2.4.4 : Linearity of CKMB activity concentration by Hitachi 911 sample-start 
method 
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2.5 Recovery Experiment 
Recovery can be used to assess accuracy in method evaluation studies. It estimates 
the amount of constant proportional error inherent, in a method and gives similar 
information as the slope that is calculated from method comparision studies. 
METHOD : Two pools of sera, A and B, were used as baseline specimens. To each pool, 
50uL, 100uL and 150uL ofBiorad control serum level 2 was added . For each specimen 
prepared ( ie，those with and without Biorad control serum level 2 addition), duplicate 
assays were performed and the two individual values averaged. 
The amount recovered was determined by subtracting the amount originaUy 
present in the respective pools from the amount measured or "observed". Per cent 
j 
！ recovery was obtained by dividing this figure by the amount added and multiplying by 100. 
I 
These individual recoveries are averaged to give an estimate of recovery. 






i :l ! 
:j ^ 
RESULTS: the estimate of recovery for the four methods used was on the whole 
satisfactory, which ranged from 100 % to 107 % . As mentioned in the method section, the 
estimate of recovery can be treated as the constant proportional error inherent in each 
method. 
For example，the Hitachi 911 reagent-start method has an estimate of 
recovery of 102 %, which corresponded to a two percent proportional error, or an actual 
error o f l . 0 U/L at activity concentration of 50 U/L .(about two times the upper reference 
range). The Dupont aca, which has the greatest estimate of recovery of 107 %, which 
corresponds to a 7 percent proportional error，or an actual error of 0.56 U/GL at activity 
concentration of 8 U/L.(again about two times the upper reference range) 
Table 2.5.1 Recovery data from Abbott EMx 
Serum pool Amount added Amount found Amt recovered Recovery 
ng/mL ng/mL ng/mL % 
A 0 5.4 —— —— 
A 4.4 10.3 4.9 111 
A 8.5 14.4 9.0 106 
A 12.2 17.7 12.3 101 
B 0 21 • 8 -— •— 
B 4.4 26.4 4,6 105 
B 8.5 29.8 8.0 94 
B 12.2 32.6 10.8 89 
Average: 101 
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Table 2.5.2 Recovery data from Dupont aca 
Serum pool Amount added Amount found Amt recovered Recovery 
m m m； % 
A 0 3.0 —— —— 
A 2.5 5.7 2.7 108 
A 4.9 8.3 5.3 108 
A 7.0 10.6 7.6 109 
B 0 9.2 —— —— 
B 2.5 11.9 2.7 108 
B 4.9 14.2 5.0 102 
B 7.0 16.8 7.6 109 
Average: 107 
-~^ T^^¾•;-a•y^g^~^•:^^^~-^•T^ ,^^l•^•^-^~«^ a^^r¾T•af^•^7=•=~-•^•;•=^:rf^g•=•;---•l:•^-gg^ -^^ •^^•s^ =^^;—•^二7fa•¾;?T=^ _^~^ :^~^7a•=•a^=^•J»vl-.7^ m^-•i-•:-J^ •^^---.•-; jr .--rg-.-.--v --;r.-^-J-=-=------: --^ -.^ ?-.^ -^ ?^^  , . - - .¾¾'? . •释• .,ii .^3^rWASS^iTZ^ TV?,"=:a.r. giljjjrSrn?-：.^ ^^  T^^J^X^S-.Sl^jL^ZfZh-Zajrf-fTF n>^> rf"d">i fT- i , T^ SajtiL^~--yg-^  i . nXiiXXl 
Table 2.5.3 Recovery data from Hitachi 911 reagent-start method 
Serum pool Amount added Amount found Amt recovered Recovery 
U/L U/L U/L % 
A 0 26.2 — — 
A 12.7 40.1 13.9 109 
A 23.6 51.4 25.2 107 
I A 33.0 60.8 34.6 105 
B 0 39.7 ---- ----
I B 12.7 52.5 12.8 101 
I B 23.6 62.3 22.6 96 
I B 33.0 71.4 31,7 96 










Table 2.5.4 Recovery data from Hitachi 911 sample-start method 
Serum pool Amount added Amount found Amt recovered Recovery 
jjrL U K 'UfL % 
A. 0 27.5 胃 - 一 —-
A 13.1 41.1 13.6 108 
A 24.3 52.9 25.4 108 
A 34.0 62.3 34.8 109 
B 0 42.5 —— —— 
B 13.1 54.4 11.9 91 
B 24.3 65.2 22.7 93 
B 34.0 72.7 30.2 89 
^ _ _ „ _ _ _ _ _ _ ^ _ _ „ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Average: 100 
2.6 Merference Experiment 
teerfering substances in the matrix of a sample are one of the causes of constant 
systematic error. The total amount of constant error is given by the Y intercept. 
Interference experiments are done to determine the cause of a significant Y intercept. 
Interference could be caused by haemolysis, hyperbiUrubinaemia, lipaemia, interfering 
drugs, analytes, etc. Only the first three catagories were considered in this study. 
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2.6.1 Effect ofhaemolysis 
METHODS : blood was taken from a healthy young adult and was separated into two 
aliquants. For the clotted blood sample, serum was harvested after centrifugation. For the 
anticoagulated blood sample, it was washed three times using 0.9% saline and the packed 
cells obtained after centrifugation were then placed in a -40^C freezer for fifteen minutes. 
The lysed cells were then taken out and allowed to stand at room temperature. The stock 
haemolysate was centrifuged and the cell debris removed. The haemoglobin concentration 
of the stock haemolysate was determined using an automated haematology analyzer 
(Coulter JR) and found to be 20 g/dL. The CKMB concentration or activity of the 
harvested serum was determined by the various methods. Various concentrations of 
haemolysate were then prepared by adding various amounts of haemolysate into harvested 
semm. To 1.5 mL of harvested serum, 150^1 of haemolysate of various concentrations 
was added . These samples were then analysed for CKMB, and for haemoglobin using a 
Coulter haemoglobinometer. 
RESULTS: the effect of haemolysis on CKMB measurement varied greatly among the 
four methods employed. Please refer to fig 2.6.1.1 to fig 2.6.1.4 for graphic presentation 
of the data. Fig 2.6.1.5 gives a visual comparison of effect of haemolysis on Hitachi 
I 
I 
丨 4 0 
！ 
I 
methods. Table 2.6.1.6 to 2.6.1.7 give summary data of effect of haemolysis on all 
methods. 
For the Abbott IMx method, there was no apparent effect of haemolysis on 
the measurement of mass concentration of CKMB，for haemoglobin levels up to at least 
910 mg/dL .The manufacturer claim was 750 mgAiL. 
For the Dupont aca method, there was a general trend of decreased activity 
of measured CKMB. At haemoglobin concentrations of up to 303 mg/dL (which 
corresponds to a visual grading of 3+ ), the effect was minimal, but the degree of 
suppressive effect was obvious as the haemoglobin concentration increased thereafter. The 
manufacturer claim was that moderate haemolysis caused interference. 
For both methods on Hitachi 911，they were subject to increasing I 
measured activity of CKMB as the haemoglobin concentration increased from very low to ‘ 
1 
- i 
910 mg/dL. The manufacturer claim was that haemolysis caused interference. ！ 
j 
The increase in measured activity of CKMB had a linear relation to the \ 
tf 
amount of haemoglobin present. From the equations of the lines on fig 2.6.1.3 and fig 
2.6.1.4, the Hitachi 911 reagent-start method can be seen to suffer from a lesser degree of 
interference from haemolysis than the Hitachi 911 sample-start method. This can be found 
by comparing the slopes of the lines. The correlation coefficients for measured CKMB 
activity versus haemoglobin concentration were very strong. For the reagent-start method, 




This apparent increase in measured activity of CKMB can be explained by 
the release of adenylate kinase (AK) from the red blood cell, which converts ADP into 
ATP and AMP. The reaction catalysed by CK also give ATP as its product, the rate of 
formation of which is monitored by sequential coupling to the hexokinase and G6PD 
reaction systems. Diadenosine pentaphosphate and AMP are added to the assay mixture as 
inhibitors of adenylate kinase. But this can eliminate the effect of AK only to a certain 
extent. The more severe the degree ofhaemolysis, the more prominent the effect ofAK . 
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Fig 2.6.1.2 : effect of haemolysis on measured CKMB activity concentration by 
Dupont aca 
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Fig 2.6.1.3 : effect of haemolysis on measured CKMB activity concentration by 
Hitachi 911 reagent-start method 
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Fig 2.6.1.4 : effect of haemolysis on measured CKMB activity concentration by 
Hitachi 911 sample-start method 
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Fig 2.6.1.5 : graph showing comparative effect of haemolysis on Hitachi 911 reagent-
start method and Hitachi 911 sample-start method 
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Table 2.6.1.6; summary data of effect of haemolysis on JMx and aca 
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Table 2.6.1.7: summary data of effect of haemolysis on 911-RS and 911-SS � 
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2.6.2 Effect of Lipaemia 
METHODS: this was investigated by adding different quantities of Intralipid 
(KabiVitmm Ltd, Uxbridge，UK) to patient serum. 24% (w/v) Intralipid was serially 
diluted with 0.9 % saline to give specimens with IntraHpid concentrations ranging from ^ 
0.23 to 120 g/L. 150^il aliquots were added to 1.5 mL human serum to give final i 
• '" -. -, - . ！ 
• ‘ > 
concentrations of Intralipid that ranged from 0.02 to 10.9 gO.. The specimens were then \ 
f 
assayed by the four methods for CKMB and for triglyceride using an enzymatic method on J 





RESULTS: the effect of Intralipid on the measured concentration of CKMB by the four 1 
) 
methods were recorded from fig 2.6.2.1 to fig 2.6.2.4. The performance of all the four ., 
methods were satisfactory. Since the triglyceride level up to 23 mmoVL caused no 
significant interference to the four methods，it was concluded that there was no significant 
difference between the mass concentration method and activity concentration methods. 
4 8 
Fig 2.6.2.1 : effect of intralipid on measured CKMB mass concentration by Abbott 
EMx 
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Fig 2.6.2.2 : effect of intralipid on measured CKMB activity concentration by 
Dupont aca 
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Fig 2.6.2.3 : effect of intralipid on measured CKMB activity concentration by 
Hitachi 911 reagent-start method 
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Fig 2.6.2.4 : effect of Intralipid on measured CKMB activity concentration by 
Hitachi 911 sample-start method 
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2.6.3 Effect ofBilirubin 
METHODS: two different pools of lyophilised external QC materials from Murex were 
used. The high bilirubin pool was reconstituted with distilled water to a third of the 
stipulated volume. The low bilirubin pool was overdiluted to three times that of its 
intended volume. These control pools were then heated for 30 minutes at 56°C to 
^ 
inactivate all CKMB activity. The absence of such activity was confirmed by assaying : 
/1 ( 
i' 
these samples for CKMB measurement. They were mixed in different proportions to give a � 
1 
series of specimens. To one part of each specimen was added two parts of human serum | 
from a healthy young man. They were then assayed for CKMB by the four methods and ( 
i 






RESULTS: the effect of total bilirubin on the measurement of CKMB of the four 
methods canbe found from fig 2.6.3.1，table 2.6.1，fig 2.6.3.2 and fig 2.6.3.3. 
For the Abbott JMx method there was no apparent increase in mass 
concentration of CKMB, so total bilirubin levels up to at least 140 ^mo^L did not 
interfere with this method. The manufacturer in fact claims that there is no significant 




For the Dupont aca method, there was a significant effect of interference 
caused by total biUrubin. When the sample had an actual CKMB activity concentration of 8 
U/L ( about 2 times the upper reference limit) and the bilirubin concentration was out of 
its normal range (i.e. greater than 21^imoH.), there was a severe suppressive effect on 
measured CKMB level to below the reference range. The manufacturer claims that 
bilirubin has a depressive efFect on CKMB measurement. ‘ 
A 
it 
For both methods of Hitachi 911 the effect of total bilirubin on their i 
measurement was not very significant. For example, when the total bilirubin concentration J 
ii ( 
of the sample was 50 i^moVL, there was only a 1.8 U/L decrease in measured activity of 
i 









Fig 2.6.3.1 : effect of total bilirubin on measured CKMB mass concentration by 
Abbott EMx 
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Table 2.6.3.1 : effect of total bilirubin on measured CKMB activity concentration 
by Dupont aca 




Remark: AlB is a flag which mean the result is less than the lower detection limit 
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Fig 2.6.3.2 : effect of total bilirubin on measured CKMB activity concentration by 
Hitachi 911 reagent-start method 
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Fig 2.6.3.3 : effect of total bilirubin on measured CKMB activity concentration by 
Hitachi 911 sample-start method 
30 ： . ,,•.,•• ^ ....,::.《：..、：,厂.,:：：. .：• : ： • ； 
• y =-0.0361x +25.076 
; ^ K - ^ ^ : ^ 




1 . . 
i 15 -o • • • • • . o … 
8 • 
0 • ’ ’ • . • • • • 
CQ .• • ‘ 
1 10— < 
o 
• ； I 
5-- i 
• • • • ： I 
. * 
0 H~~^  h-~"-~~1 ！ ‘~~^  ^ ― ~ ^ 
0 20 40 60 80 100 120 140 j 
I 
Bilirubin concentration (umoUL) , 
<i 
‘— “‘ —-' —‘—^ ~^~~^ ~^^ ~^«~~^^^~~~^~~~~~^~^ ^^~~~~^~^~~~"^^^^ • 
57 
.i 
2.7 Stability study 
AEVL: both the short term stability and long term stability were investigated in this project. 




METHODS: patient sample pools A and B were used. They were both separated into 2 I 
*i 
bottles，so that one complete set was used for the stability test at room temperature and j 
I 
another at 4°C. For the stability study at room temperature the four methods of j 
I 
measurement were used to assay CKMB level at 0，1，2，4，8, 16，42 and 96 hours in 
] 1 
dupHcate. For the stability study at 4°C, the four methods of measurement were used to , 
•“ 
assay CKMB levels at 0，42 and 96 hours in duplicate. 
RESULTS: at room temperature, for the Abbott EVIx method measuring mass 
concentration，the measured level was unchanged until 42 hours; thereafter, it increased to 
8 percent higher than the basal specimen. This was probably due to the effect of 
evaporation. It might be due to repeated opening and closing of the same bottle and to a 
large deadspace . 
5 8 
i 
For the Dupont aca method and Hitachi 911 methods the measured activity 
decreased with time. Table 3.6.1 is the data from the Hitachi 911 reagent-start method 
showing this phenomeon. At 8 hr the measured activity dropped to 94 percent of the 
original basal activity. At the same time the measured activity of aca and Hitachi 911 
sample-start methods also dropped to 98 and 91 percent of the original basal activity 
respectively. 
Table 2.7.1 : stability test result from Hitachi 911 reagent-start method 
1 I 
: f s 8 » ^ ^ ^ K ^ ^ R l ^ ^ e i ^ ^ » » ! ^ ^ ^ « « 丨 
^ ^ ^ ^ ^ ^ ^ m : 
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j At 4�C, at 42 hours，there was no change in mass concentration by the i • 












both methods of Hitachi 911. At 96 hours, there was a decrease in all methods except 
Evlx method, to a extent of about 90 percent of the basal specimen . 
2.7.2 Long term stability 
METHODS: 40 patient samples were assayed immediately after collection. The first 20 
patient samples were stored at -40°C for one month, then they were reassayed by Hitachi 
911 reagent-start method . The other 20 different patient samples were stored at -70�C 丨 
i 




RESULTS: for samples stored at -40°C for one month, the mean activities had dropped ) 
to 96 percent of the original activities. For samples stored at -70°C, the mean activities ‘ 
f 
before and after storage were virtually identical (99.5 % of the original activities). A 
former stability study by Dr M.G. Jones demonstrated similar results and it was reported 




CORRELATION AMONG THE FOUR METHODS OF 
CKMB MEASUREMENT 
In this chapter, the four methods in assaying CKMB were compared and 
investigated as to the strength of correlation among the methods. 
METHODS : during the period ofthe experiment each sample was split into four aliquots 
and stored at -70°C for not more than a month before analysis. Since the patient samples ‘ 
I 
were collected continuously over 5 months, they were assayed in several batches. Due to 
1 
the limited volume of serum obtained all the patient samples for the correlation study were ) 
assayed only once for each of the four methods. ! 
# 
RESULTS: comparison data for the four methods of CKMB measurement are shown in 
table 3.1. The following abbreviations were use and have the meanings as shown below: 
• X : reference method 
6 1 
I 
• Y : comparing method 
• N : number of samples 
• R : correlation coefficient 







































































































































































































































































































































































































































































































































































































































































































As shown in table 3.1, every method in our experiment was used as a 
reference method to compare with the other three methods. Therefore, there was a total of 
12 permutations. There were 346 samples involved in this correlation study. The 
correlation coefficients of various combinations range from 0.960 to 0.999，signifying an 
excellent correlation among the four methods. Among these combinations we found，not 
surprisingly, that the Hitachi 911 reagent-start method as reference method correlated ‘ 
best with Hitachi 911 sample-start method (R = 0.999); also the standard error o f Y on X 
for this comparison was the lowest ( Sy/x = 8.295 ). Fig 3.2 and fig 3.3 show the scatter 
plot of the best and worst correlated pairs respectively, the latter being the Dupont aca as 
reference method and Hitachi 911 sample-start as the method for comparision ( R = 0.960, 
Sy/x 二 42.9). 
Altman Bland plots of fig 3.4 and fig 3.5 using same data set as that of fig 3.2 and 
fig 3.3 were also used as another way to reveal method differences which could be missed , 
on conventional analysis. Similar conclusions can be drawn from both methods of 
j 
statistical analysis. For the best correlated pair，the mean negative bias was -9.3 with a 
95% confident interval from -25.6 to 6.9. There were six points out side of this interval 
(out of 346 samples) , which may due to random error. Also these two methods were 
subject to different degrees of interference cause by sUght haemolysis. For the worst 
correlated pair, the mean negative bias was -78.4 with a 95% confident interval from -226 
to 69.3. There were more points outside this interval (about 14) as the mean CKMB level 
increased. This may be attributed to the fact that the Dupont aca method was relatively 
6 4 
i 
unaffected by the presence of different degrees of slight haemolysis, but for Hitachi 911 
sample-start method, different degrees of slight haemolysis could raise the measured 
CKMB level significantly. Also, dilution error was the major contributor for the Dupont 
aca method (linearity up to 125 \]fL). This was the reason why the correlation between 
this two methods were worst as compared with the other pairs. 
The other 4 possible combinations for the Altman Bland Plot are also available in 
Fig 3.6 to Fig 3.9. Looking at all the Altman Bland plots the Dupont aca method stands 
out as having the worst correlation, with an increasing deviation from the other methods at 
I 
high concentrations. This was because of an unpredictable ‘matrix effect，affecting the 
micro-column caused by dilution of high CKMB level samples with zero calibrator. In the 
reagent insert of the Dupont aca method, it recommended not performing dilution for 
samples having CKMB level higher than 125 U/L and simply reporting results as > 125 
U/L. Since the deviation occurs at very high levels, weU above the decision threshold for 
«4 
diagnosing AMI, it is oflittle clinical significance. 
6 5 
•I 
Fig 3.2 : scatter plot of the best correlated methods 
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Fig 3.3 : scatter plot of the comparatively worst correlated methods 
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Fig 3.4 : Altman and Bland Plot for method comparison between Hitachi 911 
sample-start method and Hitachi 911 reagent-start method 
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Fig 3.5 : Alman and BIand Plot for method comparision between Dupont aca and 
Hitachi 911 sample-start method 
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Fig 3.6 : Altman and Bland Plot for method comparison between Abbott JMx 
method and Dupont aca method 
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Fig 3.7 : Altman and Bland Plot for method comparison between Abbott EMx 
method and Hitachi 911 reagent-start method 
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Fig 3.8 : Altman and Bland Plot for method comparison between Abbott EMx 
method and Hitachi 911 sample-start method 
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Fig 3.9 ： Altman and Bland Plot for method comparison between Dupont aca 
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Chapter 4 
ESTABLISHMENT OF REFERENCE RANGES FOR 
THE FOUR METHODS OF CKMB MEASUREMENT 
4.1. METHODS 
In this part of the experiment venous blood from 55 student nurses and 
members of staff from Caritas Medical Centre were collected for the establishment of 
reference ranges for the four methods of CKMB measurement. The ages of the subjects 
ranged from 18 to 45. There were 24 men and31 woman. Venous blood samples were 
centrifuged and the sera separated and stored at -70°C until assayed for CKMB. Total CK 
J 
was also measured in order to determine a range for the CKMB/CK ratio. 
7 1 
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Fig 4.2 : frequency distribution of CKMB mass concentration by Abbott EMx in 
healthy young adults 
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Fig 4.3 : frequency distribution of CKMB activity concentration by Dupont aca in 
healthy young adults 
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Fig 4.4 : frequency distribution of CKMB activity concentration by Hitachi 911 
reagent-start method in healthy young adults 
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Fig 4.5 : frequency distribution of CKMB activity concentration by Hitachi 911 
sample-start method in healthy young adults 
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The frequency distribution of total CK and CKMB concentration by the 
four methods are shown in fig 4.1 to fig 4.5 respectively. From the visual inspection ofthe 
distribution, they did not appear to be Gaussian: they suffered from different degrees of 
skewness to the right. These impression was confirmed by both the coefifident of skewness 
and the coefficient ofkurtosis , as shown in table 4.6. 
Table 4.6 : Assessment of various tests for Gaussian distribution 
" ™ n § n ^ ^ S ™ l O E F F I C ^ � O F S K E W N E S T ^ T 5 S ^ ^ W 5 F H J R T 0 S I S 
TotalCK r.0 -0.7 
CKMB (JMx) 2.4 8.5 
CKMB (ACA) 1.5 4.3 
CKMB (Hitachi RS) 0.83 3.4 
CKMB (Hitachi SS) 0.976 4.1 
Skewness characterizes the degree of asymmetry of a distribution around its mean. 
Kurtosis characterizes the relative degree of peaking or flattening of a distribution 
compared to the Gaussian distribution. From table 4.6, it was concluded that aU tests 
demonstrate a positive skewness, which indicates a distribution with an asymmetric tail 
extending towards more positive values. This was in agreement with the visual inspection. 
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Aiso for all tests of CKMB the coefficients ofkurtosis were positive, indicating a relatively 
peaked distribution . This was again in agreement with the visual inspection. Therefore 
parametric methods could not be used . To establish the reference ranges for these tests, a 
non-parametric method was used instead, using the 97.5 percentile as the upper reference 
limit. The results are as shown in table 4.7. Moreover, the reference ranges for 
CKMB/total CK ratio (relative index) were also found by using the same non-parametric i 
method. The results are as shown in table 4.8 . Although the author adopted an upper j 
！ 
reference limit by the non-parametric method, this must be regarded as tentative given the ！ 
• 
small sample size and the limited age range of the reference population chosen. 
I 
Table 4.7 ； reference range for various CKMB tests calculated by a non-parametric 
method 
Test name Reference range 
Total CK M o w ^ ^ " 
CKMB {JMx) below4.7 
CKMB (ACA) below4.3 
CKMB (Hitachi RS) below 25.8 
CKMB (Hitachi SS) below 26.0 
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Table 4.8 Reference range for various relative indices calculated by a non-
parametric method 
——RELATIVE^DEX REFERENCE VALUE 
(per cent CKMB/ total CK) 
JMx method below 2.2 
aca method below 2.0 
911-RS method belowll.9 
911-SSmethod below 12.0 
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Chapter 5 
• O R M A T I O N ON THE QUALITATIVE TROPONIN-
T RAPID ASSAY® 
I 
i [i 
5.1 Analytical methodology j 
i 
f 
This is a dry chemistry system requiring no instrumentation and using 
whole blood as the primary sample material. 
Reagent kit: TropT® Rapid Assay, Boehringer Mannheim, 
TEST PMNCffLE: One hundred and fifty microlitres of sample material are pipetted on 
to the sample port using a syringe. The reaction zone contains two monoclonal antibodies ‘ 
gVL^s) specific for different epitopes of the cardiac isoform of the troponin molecule. 
One MAB is gold-labeUed and the other biotinylated. The two MABs dissolve in the blood 
and bind to any troponin present to produce a double antibody troponin complex. The 
sample spreads by capiUary action along the test strip and through a fleece where 
erythrocytes (if present) are separated from the serum or plasma, the latter then diffusing 
to the detection zone. This comprises an immobiHzed streptavidin reaction zone which 
binds the double antibody sandwich with development of a red colour. The gold-labelled 
8 0 
antibody is present in. excess. Unbound gold-labelled antibody binds to a second control 
line to confirm successful sample application and sample difiusion. This technique, referred 
to as gold-linked optical read immunoassay (GLOiOA) reaction, is complete in 20 minutes 
and read as follows: no lines visible- unsuccessful reaction; one line visible- negative test 
with successful reaction; two lines visible- positive test with successful reaction. The time 









Since Troponin-T Rapid assay is a qualitative method, precision, linearity and 
i 
recovery cannot be evaluated. The following is information about interference and sample 
stability. i 
Interference: 1: haemoglobin up to 200mg/dL does not interfere with the test 
2; bilirubin does not interfere with the test 
3: Hpemia does not interfere with the test 
Sample stability: 1: at room temperature, EDTA sample is stable for 8 hours 
2: do not refrigerate EDTA sample as some particles may form which 
may block the passage of troponin-T to the detection zone. 
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Chapter 6 
CLINICAL EVALUATION OF CKMB METHODS 
AND TROPONEV-T QUALITATWE METHOD m 
DETECTION OF ACUTE MYOCARDLVL 
INFARCTION (AMI) 
6.1 Materials and Methods 
i 





The site ofthe clinical study was the Prince of Wales Hospital (PWH), a tertiary 
referral centre, attached to the medical school, and an acute hospital with a catchment 
一 ‘ 丨, 
population of about one million people. M patients suspected of AMI and who were 
admitted to the cardiac care unit (CCU) ofPWH were included in the study. 
On admission to CCU, a protocol sheet was filled in by the nursing staff (Appendix 
1). This document included demographic data and a record of the patient's cardinal chest 
pain symptom - its nature, time of onset and duration. Based on the time of onset of 
symptoms target times for blood sampling and twelve-lead electrocardigraphy were noted 
on the sheet. 
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6.1.2 Specimens 
CKMB SPECEVDENS : For each patient, a total of nine serial specimens were taken. 
These included the admission sample and samples of 1，2，3, 4，8，12, 28 and 48 hours 
after admission. Three to 5 mL of clotted blood was collected at each sampling time and 
sent to the Chemical Pathology Laboratory immediately. The samples were centrifuged for 
5 minutes at 3000 rpm and sera collected. They were stored at -70 °C before subsequent 
analysis. 
TROPONEV-T SPECEMENS: For each patient an admission blood sample anti- 丨 
1 
1 
coagulated with EDTA was collected at the patients bedside and were analysed 
immediately after coUection. 
h 
6.1.3 Criteria for diagnosis 
The diagnosis of AMI was in most cases established by a combination of history, 
electrocardiography and routine serial cardiac enzymes including AST, LDH and total 
CK, which were measured on all the blood samples coUected. The criteria used for both 
confirmation and exclusion of the diagnosis are an adaptation of those described by GiUum 
et aL [9] and are Usted in appendix 2 and 3 . bi some cases where the diagnosis remained 
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remained equivocal, a post-convalescence exercise thallium scan was required. The criteria 
used for interpretation ofthe standard cardiac enzyme profiles are listed in appendix 4 . 
6.1.4 Analytical methods 
CKMB RELATED METHODS 
1. Total CK activity: We used reagent from Boehringer Mannheim and the assay was 
performed on the Hitachi 911. 
2. CK-MB mass assay: We used reagent from Abbott and the assay was performed on 
the Abbott EMx . | 
3. CK-MB activity assay Three different methods were used in this catagory. Firstly, 
we used sample-start reagent from Boehringer Mannheim on Hitachi 911 for the without-
serum-blanking assay. Furthermore, two different protocols were used to assess which one 
was better for the without-serum-blanking assay. Secondly, we used reagent-start reagent 
from Boehringer Mannheim on Hitachi 911 for the serum blanking assay. Thirdly, we used 
reagent from Dupont for the ion-exchanged chromatography combined with 
immunoinhibition assay and the assay was performed on the Dupont aca. 
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TROPONEV-T METHOD 
4. Troponin-T assay: this is a qualitative assay-we used kits from Boehringer 
Mannheim and the test was performed at the bedside by nursing staff trained in the 
technique by BMD personnel. 
6.1.5 Statistical methods 
6.1.5.1 Calculation of Sensitivitv • Specificity and Efficiency of the tests 
The sensitivity, specificity and efiiciency of the tests were determined for the four 
methods ofCKMB measurement and Troponin-T measurement for the admission samples. 
Cut-off limits of all tests were the upper reference values for healthy young adults. 
Sensitivity is a measure ofincidence of positive results in persons known to have a disease， 
that is，a 'true positive' (TP) Specificity is a measure of incidence of negative results in 
persons known to be free of disease, that is a 'true negative' (TN). Efficiency of a test is 
given by the number of correct results，the sum of true positives and true negatives, in 
relation to the numbers of tests carried out. 
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6.1.5.2 Predictive Values and Likelihood Ratios 
Positive and negative predictive values and likelihood ratios of the four 
methods of CKMB measurement and Troponin-T measurement for the admission samples 
were calculated. Predictive value of a positive result, PPV, describes what fraction of all 
positive results are correct. Similarly, the predictive value of a negative result, NPV, 
describes what fraction of all negative results are correct results. The positive likelihood 
ratio(PLR) of a positive (ie. abnormal) result equals to sensitivity/(l- specificity), or true-
positive rate/false-positive rate. PLR is the multiplier applied to the pre-test odds to 
calculate the post-test odds of disease. If PLR is 1，then a positive result does not increase 
at all the probability of the disease being present. If PLR is infinity，it implies a 100% 
positive predictive predictive value. 
The negative likeUhood ratio fNLR) of a negative (ie. normal) result equals to (1-
sensitivity)/specificity, or false-negative rate/true-negative rate. NLR is the multiplier 
appHed to the pre-test odds to calculate the post-test odds of non-disease. If NLR is 1， 
then a negative result does not increase at all the probabiHty of the disease being absent. If 
NLR is zero，it implies a 100% negative predictive value. 
8 6 
6.1.5.3 ROC Curves 
Receiver operating characteristic (ROC) curves were generated for the four 
methods ofCKMB measurement for the admission samples and the 2-hour samples ROC 
curve is a plot of all of the sensitivity/( 1 -specificity) pairs resulting from continuously 
varying the decision threshold over the entire range of results observed. On the y-axis is 
sensitivity, or the true-positive fraction. On the x-axis is the false-positive fraction，or 1 -
specificity. Each point on the ROC plot represents a sensitivity/specificity pair 
corresponding to a particular decision threshold. A test with perfect discrimination has an 
ROC plot that passes through the upper left comer, where the true-positive fraction is 1 or 
100% (perfect specificity)，and the false-positive fraction is 0 (perfect specificity). The 
theoretical plot for a test with no discrimination is a 45° diagonal line from the lower left 
comer to the upper right comer. Most plots faU in between these two extremes. Areas 
under the ROC curve were calculated, along with the standard error of the area. This 
enabled a comparison ofthe areas to be made to determine whether the difference between 
them was statisticaUy significant. 
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6.2 RESULTS: 
76 suspected AMI patients were included during the experimental period and of 
these 54 were classed as AMI cases. 22 cases were diagnosed as non-AMI cases. 
Therefore the prevalence ofAMI in CCU ofPWH is 71%. Most of the non-AMI cases 
had evidence of ischaemic heart disease, the most common final diagnosis being unstable 
angina. 
The dot diagram of CKMB level measured by the four methods of the admission 
samples (before thrombolytic treatment) in CCU was shown in Fig 6.1. The true positive， 
false positive , true negative，false negative, sensitivity, specificity，efficiency，positive and 
negative predictive values, positive and negative likelihood ratios for the four methods of 
CKMB measurement and the quaHtative Troponin-T using the upper reference Umit as the 
cut-ofF limit for admission and 2-hour after admission samples are shown in Table 6.2.1 
and Table 6.2.2 respectively. 
ROC curves of the four methods of CKMB measurement for the admission 
samples are shown in Fig 6.3 to Fig 6.6. ROC curves of the four methods of CKMB 
measurement for the 2-hour samples are shown subsequently in Fig 6.7 to Fig 6.10. Areas 
under the ROC curves, and their respective standard errors are given in Table 6.11 and 
Table6.12. 
8 S 
Fig 6.1 : dot diagram showing admission CKMB level by the four methods 
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1. Abbott Evlx method 
2. Dupont aca method 
3. Hitachi 911 reagent-start method 
4. Hitachi 911 sample-start method 
Table 6.2.1 : sensitivity, specificity, efficiency, predictive values and likelihood ratio 
for each method performed on the admission sample _ „ „ ^ „ ^ „ » > « „ » _ _ ~ ^ 
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Fig 6.3 : ROC curve of Abbott EMx method of CKMB measurement for the 
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Fig 6.5 : ROC curve ofHitachi 911reagent-start method of CKMB measurement for 
the admission sample 
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Fig 6.7 : ROC curve of Abbott EMx method of CKMB measurement of the 2-hour 
sample 
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Fig 6.9 : ROC curve of Hitachi 911 reagent-start method of CKMB measurement of 
the 2-hour samjgle — _ _ „ _ _ _ _ _ _ _ _ _ ， 
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Table 6.11 : area under ROC curves of admission samples for CKMB methods 
""""""" “‘ _I """"'" 
CKMB methods Area under ROC Standard Error 
D ^ ^ ^ 
aca 0.81 0.05 
911-RS 0.81 0.05 
911-SS 0.83 0.05 
脆 - R I 0.77 0.05 
卿 - R I 0.78 0.06 
911-RS-RI 0.69 0.07 
911-SS-RI 0.70 0.06 
Table 6.12 : area under ROC curves of 2-hours samples of CKMB methods 
CKMB methods Area under ROC Standard Error 
_Svfcc — 0:97 : 0.02 
aca 0.96 0.02 
911-RS 0.86 0.05 
911-SS 0.86 0.05 
脆 - R I 0.90 0.04 
aca-RI 0.89 0.04 
911-RS-RI 0.90 0.04 
911-SS-RI 0.92 0.03 
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6.3.1 Comparision among CKMB methods and between CKMB and the Troponin-
T assaY 
Since the Troponin-T assay in this experiment was a quaHtative one，this limits the 
comparison with CKMB methods. Therefore, sensitivity , specificity, efficiency, predictive 
value and likehood ratios were primarily used for comparing their performance for the 
admission samples and 2-hour samples after admission. 
Sensitivity: For admission samples among CKMB methods, Hitachi 911 sample-start 
method had the highest sensitivity (94%)and Dupont aca method had the lowest 
sensitivity(60%). Troponin-T had a sensitivity of only 40%. For 2-hour samples, 
Troponin-T had a sensitivity up to 65%，while CKMB methods had a sensitivity over 
86%., so in this respect the performance of the CKMB methods was better. 
Specificity: For admission samples among the CKMB methods，the Abbott EVbc method 
and Dupont aca method had the highest specificity (86%) and the Hitachi 911 sample-start 
method had the lowest specificity (45%). Troponin-T had a specificity of 100%. Result 
from 2-hour samples was similar to admission samples，so in this respect the performance 
ofTroponin-T method was better. 
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Efficiency: For the admission samples among the CKMB methods, the Hitachi 911 
sample-start method had the highest efficiency (80%) and the Dupont aca had the lowest 
efficiency(67%). Troponin-T had an efficiency of only 60%. Result from 2-hour samples 
was similar to the admission samples，so in this respect the performance of CKMB 
methods was better. 
Positive predictive value: For the admission samples among the CKMB methods, EVbc 
had the highest percentage of correct positive results (93%) and Hitachi 911 sample-start 
method had the lowest percentage of correct positive results. Troponin-T had 100% of 
positive results correct. For the 2-hour samples, Troponin-T also had 100% of positive 
results correct, so in this aspect performance of Troponin-T method was better. 
Negative predictive value: For admission samples among CKMB methods，Hitachi 911 
sample-start method had the highest percentage of correct negative results(77%) and 
Dupont aca had the lowest percentage of correct negative results(48%). Troponin-T had a 
negative predictive value of 43%. For 2-hour samples, Troponin-T also had lowest 
negative predictive value, so in this respect the performance of the CKMB methods was 
better. 
Positive likelihood ratio: For the admission samples among the CKMB methods, Abbott 
JMx had the highest positive HkeHhood ratio(5.4) and Hitachi 911 sample-start method had 
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the lowest positive UkeUhood ratio(1.7). Troponin-T had a positive HkeUhood ratio of 
infinity implying a positive predictive value of 100 %. Similar result was obtained from the 
2-hour samples, so in this respect the performance of Troponin-T method was better. 
Negative likelihood ratio: For the admission samples among the CKMB methods, Hitachi 
911 sample-start method had the lowest negative UkeUhood ratio (0.13) and Dupont aca 
had the highest negative likelihood ratio. Troponin-T method had a negative likeHhood 
ratio of 0.6. Similar result was obtained from 2-hour samples，so in this respect the 
performance ofthe CKMB methods was better. 
From the above information, a very striking performance of the qualitative 
troponin-T，namely its the 100% specificity was found. A CKMB test with 100% positive 
predictive value wouldl make it suitable to confirm AMI in CCU. If the cut-offvalue of 
CKMB tests was adjusted to make a 100% specificity, then the corresponding sensitivity 
for confirming AMI patient can be directly compared. The result was shown in table 6.13.1 
and 6.13.2 
Table 6.13.1 : comparison of CKMB methods and Troponin-T at 100% specificity 
for the admission sample _ _ _ — — — ^ — 
P H I - B a ^ E g 1 i > i y i i M i i M M M I I 
CKMB ^, T . . . . . 
j ^ 48 100 63 100 44 Infinity 0.52 
aca 46 100 62 100 43 Infinity 0.54 
911 RS 33 100 53 100 38 Infinity 0.67 
9H-SS 36 100 55 100 39 Infinity 0.64 
EVlx-RI 33 100 53 100 38 Mnity 0.67 
aca-RI 17 100 41 100 33 Mnity 0.83 
TROP 
TROPOND^-T 40 100 60 100 43 Mnity 0.6 
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Table 6.13.2 : comparison of CKMB methods and Troponin-T at 100% specificity 
for the 2-hour after admission sample 
CKMB 
JMx 80 100 86 100 69 Infinity 0.2 
aca 76 100 83 100 65 Infinity 0.23 
911-RS 33 100 52 100 39 Infinity 0.67 
911-SS 27 100 49 100 37 Infinity 0.73 
EVIx-RI 45 100 62 100 42 Infinity 0.55 
aca-RI 34 100 54 100 40 Infinity 0.66 
TROP 
TROPOMN-T 65 100 74 100 50 Infinity 0.35 
For the admission samples, the diagnostic sensitivity of Abbott M x method and 
Dupont aca method were 48% and 46% respectively when the diagnostic specificity was 
100%. This corresponds to a cut-ofFvalue of 25.5 ( 5.4 times the upper reference Hmit) 
for Abbott JMx and 17.1 ( 4.0 times the upper reference Hmit) for Dupont aca.The 
diagnostic sensitivity ofTroponin-T was 40%. The overaU diagnostic efficiency of Abbott 
JMx and Dupont aca were 63% and 62% respectively, compare to 60% of Troponin-T. 
Therefore the performance of CKMB methods using Abbott JMx and Dupont aca were as 
good as quaHtative Troponin-T in confirming in AMI. 
For the 2-hour after admission samples, the diagnostic sensitivity of Abbott JMx 
method and Dupont aca method were both higher than Troponin-T and the overaU 
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diagnostic emciency ofAbbot JMx and Dupont aca is better than Troponin-T. Therefore, 
the performance ofAbbott JMx and Dupont aca were better in confirming AMI 
Due to the release kinetics of CKMB, it was not possible to adjust to a 100% 
sensitivity and compare the corresponding specificity of the two markers for the admission 
samples. A cardiac marker with 100% in sensitivity was very useful to rule out AMI 
patient. 
6.3.2 Comparison ofCKMB methods for admisson sample by ROC curves 
The discriminating power oftests can be shown by their respective areas under the 
curve. So from table 6.11, the discriminating power in descending order was Abbott JMx 
(0.86)，Hitachi 911 sample-start method(0.83), and Dupont aca and Hitachi 911 reagent-
start method (both 0.81). The various CKMB relative indices were not superior to 
individual CKMB measurements alone. Abbott EVfa: apparently had the highest 
discriminating power at the time of admission, although it was not statisticaUy significant 
when the standard error under the curve was taken into consideration due to the low 
number of subjects studied. 
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6.3.3 Comparison ofCKMB methods for 2-hour sample bv ROC curves 
Refer to table 6.12. The discriminating power of Abbott JMx and Dupont aca 
could not be distinguished from each other statisticaUy although Abbott JMx had the 
highest power among the four CKMB methods. The discriminating power of the Hitachi 
methods seemed to improve when using their relative index at two hours post-admission, 
but there was no obvious explanation for this finding. 
6.3.4 How to choose the optimal decision threshold ？ 
One ofthe advantages of plotting ROC curves is the visual location ofthe optimal 
decision threshold which is nearest to the upper left hand comer. Unfortunately, in our 
case, the curve is too bumpy. This may due to the smaU sample size. Even though the 
curve is smooth, we can only locate a range of possible thresholds near to the upper left 
hand comer. 
One ofthe ways to locate the optimal threshold is by plotting various cut-offvalues 
against sensitivity/specificity. For example, this is showed on fig 6.14 for the Hitachi 911 
reagent-start method. 
‘、 
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Fig 6.14 : plot of Sensitivity / Specificity against various cut off values ofHitachi 911 
reagent-start method 
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Cut off values 
As shown in this figure，a drop in sensitivity from 1 is in exchange for a gain in 
specificity. I fwe consider sensitivity is as important as specificity, a ‘compromise point, 
where these two curve meet can be chosen. For the Hitachi 911 reagent-start method, this 
cut-ofFis about 30 U/L. 
There are two drawbacks to the above method. Under cUnical conditions, the 
prevalence and the relative cost of false positive and false negative results should be 
considered. Ifthe test is used in CCU，the high prevalence of 71% ofAMI in the patient 
population should be considered. This is because，if the sensitivity of the test is low, there 
wiU be more false negative cases than false positive ones. Therefore an increase in 
sensitivity by lowering the cut-off value wiU decrease the absolute number of false 
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negative cases to a greater extent than it wiU increase the number of false positive cases. 
This means the optimal cut-off value, when considering the high prevalence using the 
above method, should shift more to the higher sensitivity side, that is to the left of the 
'compromise point，. When applying this method，the cut-off point which gives the highest 
efficiency with a slight decrease of specificity for the Hitachi 911 reagent-start method is 
approaching to the upper reference value. 
Another factor we have to consider is the relative cost a consequence of false 
positive and false negative results. In the detection of AMI, unnecessary treatment with 
thrombolytic agents is not without risk for the patient falsely classified as a positive case; 
on the other hand, delay in giving thrombolytic treatment to real AMI patients affects the 
prognosis and outcome in false negative cases. On the whole, the risk of treatment is far 
outweighed by the risk of non-treatment. Therefore，when considering this relative false 
positive/false negative cost ratio, a higher false positive rate can be more acceptable than a 
false negative rate. The test should then be shifted more to the higher sensitivity side. In 
considering the high prevalence and the relative false positive/false negative ratio, the 
optimal threshold is more or less to the left of the ‘compromised point，，which gives the 
highest diagnostic efficiency. 
FinaUy, it should be emphasized that choice of an optimal cut-off may be very 
difficult cHnical decision for the clinician because more factors may be taken into 
consideration. Jn CCU, because of the high prevalence of AMI，use of a cut-off favouring 
higher sensitivity and fewer false negatives is desirable when the patient is first admitted to 
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c c u . Therefore, this cut-offmay not be directly transferred to other cHnical settings. For 
example, if CKMB were used as a screening test in the Accident and Emergency 
Department or in general wards for patients with only a low cHnical index of suspicion for 
AMI, a cut-offwith high specificity is necessary due to the low prevalence of AMI. Also, 
for a given level of specificity, the sensitivity of the four methods of CKMB measurement 
may increase at a later time after admission, due to increased appearance ofCKMB release 
from myocytes into the blood stream. 
6.3.5 Suggested diagnostic thresholds for clinical decision making 
Three decision thresholds are suggested for cMcal decision making. The first 
useful threshold is the measurement which gives 100% sensitivity. This is useful for ruling 
out AMI patients. The second useful threshold is the measurement which gives 100% 
specicity, this is useful for confirming AMI patients. The final useful threshold is the 
measurement which gives the highest diagnostic efficiency，when used together with the 
results from other diagnostic tools，such as ECG, to give the probability of AMI. Using 
the Hitachi 911 reagent-start method result, ifthe CKMB level were below 10.3 U/L，this 
would definitely rule out AMI; if the CKMB level were above 73.3 U/L, this would 
definitely confirm AMI; ifthe CKMB level were 29.6 IJTL，this would, on balance, make 
AMI a more likely diagnosis. 
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Chapter 7 
GENERAL DISCUSSION 
Classical evolutionary changes on the electrocardiogram (ECG) over several days 
have a 100% diagnostic specificity for acute myocardial infarction(AMI). Sometimes, 
however, the ECG may not be diagnostic. The need to improve the accuracy and rapidity 
of the triage and management of patients with chest pain has inspired the investigation of 
whether "stat" measurements ofmarkers ofmyocardial injury can lead to the diagnosis of 
acute myocardial infarction more rapidly. Enthusiasm for his strategy has been facilitated 
by the development of rapid analytical techniques. Jf assays of adequate diagnostic 
- accuracy are available and at the same time have a short turnaround time (TAT), these 
techniques for investigation of chest pain can be used to 
1. conserve resources when initial suspicion of infarction is low 
2. identify patients with infarction appropriate for early intervention, e.g. thrombolytic 
therapy 
3. avoid premature hospital discharge of patients with infarction 
It is widely accepted that early thrombolysis wiU reduce AMI mortality by one third 
from 10 - 15% in the pre-thrombolysis era to 5 - 10% now [39]. Jn Hong Kong, Woo et 
al. reported that the AMI mortality in the pre-thrombolytic and thrombolytic eras were 
1 0 5 
27.1% and 18.6% respectively [40]. Therefore, certain assays can aid in minimizing 
omissions ofindicated thrombolytic therapy and help to reduce the mortaUty rate in Hong 
Kong. 
In this dissertation, two markers for AMI were studied for their usefuhiess in 
accurate diagnosis, CKMB measurement being studied in greater detail than Troponin T. 
Four methodologies of measurement of CKMB were evaluated for their analytical 
performance. 
CKMB mass concentration by Abbott JMx assay showed minimal interference by 
haemoglobin, biHrubin and intraHpid at high concentration. But this mass assay was 
comparatively imprecise with respect to the activity assay of the Hitachi 911. This is 
consistent with findings in other studies[41]. In the study ofMaijan et al, the between-run 
precision(% CV) was as high as 14%; but in this study, the between-run precision was 
<6.1%. The reason for this difference may be due to the length of study. The study period 
was only 5 months in this study while it was one year in Maijan et al study. Alternatively it 
may represent variations among EMx instruments or technical variations in operator skiU-
for the present study aU measurements were performed by a single operator on a single 
instrument. One might ask what is the analytical goal ？ The common target is an analytical 
CV less than one halfthe intraindividual variation; for CKMB, the goal is a % CV ofless 
than 15.6 [42]. 
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For the CKMB activity concentration assays, attempts to improve the specificity 
of the Dupont aca DEC method by including a column to reduce the interference by AK 
and macro-CK was made which make this assay more specific than ordinary 
immunoinhibition activity assays such as those employed on Hitachi 911. On the other 
hand，the precision of this assay is not as good as those on the Hitachi 911. Also, 
heparinized samples can not be used because of possible matrix effects. When normal 
saHne was used for sample dilution purposes, the result did not always agree with those 
using zero protein matrix calibrator. The immunoinhibition method employed by the 
Hitachi 911 sample-start method and reagent- start method were the most precise 
methods, but both suffered from serious interference from haemoglobin. The reagent-start 
employed the strategy of "true serum blank" in the hope of eUminating the effect of 
haemolysis that exists in the sample start method. The result was not that promising, as the 
extent ofreduction was less than expected. From the viewpoint of analytical performance, 
the Abbott JMx mass assay is better than the three activity assays. 
One objective ofthe clinical study was to determine whether qualitative Troponin-
T was effective for diagnosis of AMI in the admission samples. Release of Troponin T_ 
from the cytosoHc pool may enable earHer detection of AMI than other cardiac markers if 
a low cutoff concentration is used. However, the results showed a clinical sensitivity of 
only 40 % for the admission sample, which was insufficient for effective early diagnosis. 
These findings are in agreement with those ofMair et al.[43], who employed a quantitative 
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method ofTroponin-T but using the same cut-offvalue, and the sensitivity was 57% for 
emergency department patients at a mean time ofpresentation of 4 hours after the infarct. 
Mair et al also compared sensitivities ofCKMB mass, quantitative Troponin T , Troponin 
I and myoglobin at 2 hours after admission up to 10 hours after admission, they found that 
these cardiac markers had smaU and not significant difference in sensitivity at these interval 
[44]. 
ROC curves were generated for the four methods of CKMB measurement: the 
Abbott mass assay and Dupont aca ffiC activity assay demonstrated better discriminating 
power than the activity methods on Hitachi. Since the Troponin-T method employed in 
this experiment was a quaHtative one，ROC curves could not be generated to compare the 
discriminating power ofthis marker with CKMB. M one experiment, Wu et al. generated 
ROC curves to compare the discriminating power ofCKMB with quantitative Troponin-T 
[45]，CKMB was superior to Troponin-T in the diagnosis ofAML 
Not only is CKMB a useful marker for the diagnosis of AMI, but also serial 
sampUng of CKMB can be used to monitor coronary reperfusion. An early increase in 
CKMB levels and a shorter time to peak CKMB have been found to be indicators of 
reperfusion. A 2.2-fold increase in CKMB in patients with inferior myocardial infarction 
and a 2.5-fold increase in those with anterior myocardial infarction during the initial 90 
minutes of treatment were reasonably sensitive (77% and 92 % respectively) and 
specific(100% ) for the detection of reperfusion[46]. 
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Which method of CKMB measurement is to be preferred ？ 
Besides analytical and cHnical performance, other factors such as cost and 
workflow should be taken into consideration when choosing a method. 
A scoring system to identify the preferred method was developed from the 
candidate methods. Points were given to each method for every factor under 
consideration. Four points were given to the method performed best in a particular factor, 
three points to the second best，two points to the third best and one point to the most 
inferior one. Li case where, for example, four methods had equal performence, the 
(4+3+2+1)/4 = 2.5 points were given to aU methods. The result is shown in table 7.1 
Table 7.1 : evaluation of choice of CKMB methods 
Factors Abbott EVlx Dupont aca Hitachi RS Hitachi SS 
1. Performance: 4 3 2 1 
a: analytical performance 
b: cUnical performance 
4 
2. Cost: 3 2 1 4 
a: reagent and control cost 
b: reagent stabiHty 
3. Workflow consideration: 4 1 3 3 
a: TAT 
b: user-friendly analyser 
c: backup analyser 
Total score: 11 6 6 8 
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1, Performance 
0. Analytical performance: the criteria in aUocating points according to results of the 
experiment. 
h Clinical performance: this is again based on the result of the experiment. 
2. Cost 
a. Reagent and control cost: Dupont aca method is the most expensive. It may be 
approximately 1.5 times that of the Abbott JMx. Hitachi 911 methods are cheaper than 
Abbott JMx method，but reagent wastage is a potential problem, especially for Hitachi 911 
reagent-start method (see below). 
b, Reagent stability : the Dupont aca reagent pack is stable for as long as one year. The 
Abbott JMx reagent pack is stable for eight months. For both the Hitachi reagent-start 
method and sample-start method, the reconstituted reagent is stable for only two weeks. 
Since the bottle size ofthe reagent-start methodis 180 tests per bottle and the bottle size 
of the sample start-method is 10 tests per reagent bottle ( but two 2.5 ml bottles are 
required since 2.5 ml is the dead volume of the reagent well), severe reagent wastage is 
foreseen ifthese methods are chosen，especiaUy that of the reagent-start method with a 
low volume oftest requests. 
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3. Workflow considerations 
0. TAT (turnaround time) 
Tests turnaround time: After loading sample and controls, Abbott EVIx requires 
approximately 20 minutes, and the other methods 30 minutes for an available result. 
CaHbration is not necessary before analysis as long as the reagent expiratory date is not 
reached and the recommemded calibration interval is not reached. 
CaUbration time: The time required for the Dupont aca method is the longest，which may 
be approximately 1.5 hours. The other three methods require about 20 minutes. 
CaHbration can be performed in the same run with any cHnical samples present in the 
Abbott IMx and Hitachi method. Calbration and clinical samples must be performed in a 
different run in the Dupont aca method. 
Reagent preparation time: Abbott JMx reagent packs can be used immediately after 
removing from the fridge. The Dupont aca reagent pack needs to warm up to room 
temperature first, involving a 15-minute delay after removing from the fridge. Hitachi 
methods require 15 minutes for reagent reconstitution with buffers. 
b, User-friendly analyser: M three analysers are equaUy easy to operate. 
1 1 1 
i 
a Backup analyser availability: hi PWH there are four Abbott EVbc analysers，two 
Hitachi 911 analysers and only one Dupont aca analyser. Therefore should the Dupont aca 
be broken down, a stat CKMB service on Dupont aca would be suspended for a certain 
period of time. 
Therefore，according to the above analysis and observation, Abbott Bdx method is the 
method ofchoicefor launching a stat CKMB assay in the Prince of Wales Hospital 
1 1 2 
Appendix 1 
AMI Markers Study 
Patent's Name Sex: M F 
HKIDNo. Date ofbirth 
Race: Chinese H Age 
Other (specify) 
MAIN anterior chest pain? ^ (tick) 
SYMPTOM: other pain? (specify location) 
other symptom? (specify) 
Date/time of onset of symptom: / / : 
am/pm 
(dd) (nun) (yy) 
Duration ofsymptom h min 
FIBRINOLYTICS 
Date/time infusion started? / / ： anVpm 
(dd) (mm) (yy) 
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'• . •• ,•• . .' . ..--:-.-::::..+•:,....•.....;:;•'. ::• 
TROP T RAPID ASSAY RESULT: 
Positive 3 Negative ^ kivalid ^ (please tick) 
Date/time of blood collection) / / : anVpm 
(dd) (mm) (yy) 
. . . ; ; : ; : i ; ; ; ; v ; ; ) M ^ i w 0 ^ ^ V ： 、 . : . . . : , : 、 ： - : - . . . 、 . : ： : : - . : . ' ) : . : 」 : 吊 : . : . ; : : : 口 : : : : : 一 . : 冗 . . 
Sampling Intervals Target sampling Actual Sampling 
Times Times 
hours after fibrinolytics Date Time Date Time 
infused (or admission if 









I 48 ] 
FEVAL DLVGNOSIS 
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Appendix 2 
Diagnostic criteria for a definite AMI 
(adapted from Gillum RF et al. Am Heart J 1984; 108: 150-158) 
One or more of the following must be fulfilled: 
1. An evolving diagnostic ECG (a minimum of two recordings), showing the 
development of pathological Q waves (at least 30 milliseconds long and >25% of the 
amplitude of the following R wave). 
2. A diagnostic ECG (ie. the presence ofeither pathological Q waves already present in 
the first recording or the combination of ST elevation and (in the absence ofventricular 
conduction defects) T wave depression) if no previous history of AMI or if previous 
infarct changes in different leads. 
PLUS 
"Positive" enzymes (See appendix 4) 
3. Prolonged cardiac pain (pain anywhere in the anterior chest，left arm or jaw +/_ pain 
in the back, shoulder(s), right arm or abdomen，the duration exceeding 20 minutes) 
PLUS 
“Positive，，enzymes (See appendix 4) 
4. A positive autopsy diagnosis 
1 1 5 
5. Positive exercise thallium scan in the absence of a previous history ofAMI 
PLUS 
“Positive” enzymes. (See appendix 4) 
1 1 6 
Appendix 3 
Criteria for exclusion ofAMI 
(adapted from Gillum RF et al. AM Heart J 1984; 108: 150-158) 
For the definite exclusion of AMI all of the foUowing criteria must be fulfilled (unless 
definitely excluded at autopsy): 
1. Absence of an evolving diagnostic ECG 
2. Absence of a diagnostic ECG on the first recording unless also one or more of the 
following: 
(a) a previous history ofAMI with documented changes in the same leads; 
(b) negative enzymes (see appendix 4) 
3. Absence of "positive" enzymes (see appendix 4) 
4. Absence of "equivocal enzymes" (see appendix 4) 
UNLESS 
Exercise thaUium scan is negative. 
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Appendix 4 
Enzyme criteria 
(adapted from Gillum RF et al. Am Heart J 1984; 108: 150-158) 
Time intervals indicated below refer to the number of hours since the onset of cardiac 
symptoms. 
Criteria for "Positive" Enzymes 
Both plasma total CK and AST > URL (ie. greater than the upper reference limit for the 
healthy adult population) within 48 +/- 8 hours 
PLUS 
Plasma total LD > URL within 72 +/- 8 hours. 
Peak plasma levels should be > or equal 2 x URL for at least two of the three enzymes. 
Criteria for "equivocal" Enzymes 
Enzyme results which do not fulfil the criteria for being positive but in which two or more 
ofthe following occur: 
1. Plasma total CK > URL within 48 +/- 8 hours 
2. Plasma AST > URL within 48 +/- 8 hours 
3. Plasma total LD > URL within 72 +/- 8 hours 
1 1 8 
Criteria for "Negative Enzymes，， 
Complete sets of enzymes (ie. results for all of the stipulated time intervals from 12 +/- 2 
hours after the onset ofsymptoms onwards) which are neither "positive" nor "equivocal". 
"Incomplete" Enzymes 
There are any set of enzyme results which do not fulfil the criteria for being positive， 
negative or equivocal. 
1 1 9 
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